BRETEC — Bioretec Oy Share News
0.000.00%
Last trade - 00:00- €30.86m
- €27.17m
- €3.52m
Brief: Bioretec Receives CE Mark Approval For Remeos Trauma Screw Product Portfolio
Brief: Bioretec's Says Finnish Financial Supervisory Authority Imposed Penalty Payment On Member Of Co's Board Of Directors
Brief: Bioretec Issued New Shares To Raise About EUR 5 Mln
Brief: Bioretec Completes Private Placement Raising EUR 6 Million
Brief: Bioretec Signs Sales And Distribution Agreement With TSB
Brief: Bioretec Enters Into New Logistics Agreement In U.S.
Brief: Bioretec 9M EBITDA EUR -3.217 Million
Brief: Bioretec Updates Financial Targets
Brief: Bioretec Sees Net Sales Will Be More Robust In Second Half
Brief: Bioretec H1 EBITDA EUR -1.864 Million
Brief: Bioretec Says Now Anticipate That CE Mark For RemeOs Will Be Issued Later Beyond Q2 2024
Brief: Bioretec Reports Successful Clinical Outcomes From U.S. Controlled Launch Of Remeos™ Trauma Screw
Brief: Bioretec Says Alan Donze Has Been Appointed As Bioretec's New CEO
Brief: Bioretec Q1 EBITDA EUR -1.112 Million
Brief: Bioretec's RemeOs Biodegradable Magnesium Alloy Composition Has Been Allowed A Patent By U.S. Patent Office
Brief: Bioretec Gets FDA Breakthrough Device Designation Status For Remeos Spinal Interbody Cage
Brief: Bioretec Oy Says European Market Authorization Application Of RemeOs Trauma Screw Has Progressed To Expert Panel Stage
Brief: Bioretec FY EBITDA EUR -2.833 Million
Brief: Bioretec: Board To Initiate New CEO Recruitment Process